1. Immunology/Inflammation
  2. Thrombopoietin Receptor

Thrombopoietin Receptor

Thrombopoietin (TPO) is the major regulator of megakaryocytopoiesis and platelet formation. The protein encoded by the c-mpl gene, CD110, is a 635 amino acid transmembrane domain, with two extracellular cytokine receptor domains and two intracellular cytokine receptor box motifs. Upon binding of thrombopoietin CD110 is dimerized and the JAK family of non-receptor tyrosine kinases, as well as the STAT family, the MAPK family, the adaptor protein Shc and the receptors themselves become tyrosine phosphorylated.

TPO binds to the thrombopoietin receptor (TPOr, also termed c-mpl) on platelets, megakaryocytes, and pluripotent stem cells leading to inhibition of apoptosis of stem cells and megakaryocytes; increased megakaryocyte number, size, and ploidy; increased rate of megakaryocyte maturation and platelet count; and decreased platelet threshold for activation by ADP and collagen.

Thrombopoietin Receptor Related Products (5):

Cat. No. Product Name Effect Purity
  • HY-15306
    Eltrombopag Agonist 99.61%
    Eltrombopag(SB-497115) is a new, orally active thrombopoietin-receptor (c-mpl) agonist that stimulates thrombopoiesis.
  • HY-15306A
    Eltrombopag Olamine Agonist >98.0%
    Eltrombopag olamine is a new, orally active thrombopoietin-receptor (c-mpl) agonist that stimulates thrombopoiesis.
  • HY-13463
    Avatrombopag Agonist
    Avatrombopag(AKR-501; AS1670542) is a novel orally-active thrombopoietin(TPO) receptor agonist with EC50 of 3.3 nM.
  • HY-100380
    TPO agonist 1 Agonist >98.0%
    TPO agonist 1 can increase production of platelets by stimulating the TPO receptor in people with chronic ITP.
  • HY-19883
    Lusutrombopag Agonist 98.81%
    Lusutrombopag is an orally bioavailable thrombopoietin (TPO) receptor agonist, used for treatment of chronic liver disease.